The annual general meeting of Gerresheimer, a global player in drug packaging and drug delivery systems, has expressed its confidence in the management board and supervisory board on the growth course embarked on by the company, recording high approval rates for all agenda items.
The company is paying its shareholders a dividend of 1.25 Euros for the past financial year 2022. At the same time, the meeting approved the creation of new authorized and conditional capital, giving Gerresheimer the option to be flexible when financing its planned further growth. CEO Dietmar Siemssen reaffirmed the company’s forecast, with revenues and adjusted EBITDA expected to grow organically by at least 10 %.
“Today, Gerresheimer is a profitable growth company — and I believe that our best years lie ahead of us,” said Dietmar Siemssen, CEO of Gerresheimer AG: “As a provider of systems and solutions, we are a key strategic partner of the pharma and biotech industries and are growing in all areas. In particular, medical devices for biopharmaceuticals, including the new GLP-1 applications, are offering us excellent growth opportunities.” The company is also aiming for double-digit growth rates in revenues and adjusted EBITDA in the coming years.
Dividend of 1.25 Euros
The meeting approved a dividend of 1.25 Euros per share for the financial year 2022. This corresponds to a payout ratio of around 27 % of adjusted net income, which is once again at the upper end of the 20 % to 30 % range defined by Gerresheimer. The dividend is to be paid out on 12 June 2023.
In the financial year 2022, Gerresheimer recorded a strong performance in a challenging economic environment, generating revenues of 1.82 billion Euros and adjusted EBITDA of 354 million Euros.
High approval rates
With 81.27% of the share capital present, the annual general meeting adopted all resolutions by a large majority. As a result, the actions of the management board and supervisory board were approved by a large majority. Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was elected as auditor for the financial year 2023.
Gerresheimer is a global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems.
